Healthcare Media & Clinician Networks
Doximity vs Sermo
Structured technology and market comparison · 2026
Direct Feature Comparison
Doximity · vs · Sermo| Attribute | ||
|---|---|---|
| Market Cluster / Sector | Healthcare Media & Clinician Networks | Healthcare Media & Clinician Networks |
| Business Model / Role | MarTech Vendor · B2C Consumer App / Platform | Publisher & Media Owner · Data Provider / Broker |
| Platform Focus | Clinician network and healthcare workflow platform monetised via enterprise tools. | Verified clinician network monetised through research, insights and healthcare advertising. |
| Company Size | 501–1,000 employees | 201–500 employees |
| Headquarters | United States | United States |
| Year Founded | 2010 | 2000 |
| Dossier & Alternatives |
Analyze all overlapping signals and tech stacks for Doximity and Sermo
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Doximity and Sermo?
Doximity and Sermo both leverage verified clinician networks to connect healthcare professionals with enterprise buyers. While Doximity focuses on healthcare workflow integration and professional utility to drive clinician engagement, Sermo emphasizes peer-to-peer discussion and professional community sentiment. Doximity serves health systems and pharma via productivity tools, whereas Sermo primarily targets life sciences through market research and insights-driven advertising.
How do the features of Doximity and Sermo compare?
Doximity provides robust clinical workflow tools, including HIPAA-secure telehealth, AI-assisted messaging, and digital faxing. In contrast, Sermo centers its product suite on market research capabilities, drug rating databases, and social sentiment tracking. While both offer targeted advertising, Doximity excels in daily productivity integration, whereas Sermo offers superior depth in clinician feedback loops and large-scale healthcare market insights.
What are the top alternatives to Doximity and Sermo?
When evaluating Doximity and Sermo, enterprise buyers also consider other platforms in Social Platform, Social & Digital Platforms, and Native & Contextual Ads. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Doximity and Sermo compare?
Doximity is headquartered in United States (founded in 2010) with 501–1,000 employees. Sermo is based in United States (founded in 2000) with 201–500 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Doximity vs Sermo
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Doximity
Recent Signals
- ·SEC APIM&A & Corporate Finance
Doximity Reports Q2 Fiscal 2027 Revenue of $174.5 Million and Lower Net Income
Doximity, Inc. reported financial results for the second fiscal quarter ended September 30, 2026, generating revenue of $174.5 million, up 4% year-over-year from $168.5 million. Growth was primarily driven by subscription revenue expansions and new customer additions. However, net income fell 44% year-over-year to $34.7 million from $62.1 million, impacted by higher cloud hosting and software infrastructure costs to support AI initiatives, as well as an increase in stock-based compensation and operating expenses. Operating income for the quarter reached $43.9 million compared to $63.7 million in the prior-year period. Doximity repurchased 2.5 million shares of Class A common stock for $54.4 million during the quarter and settled its final contingent earn-out liability related to the AMiON acquisition. The company also reached a confidential settlement dismissing the OpenEvidence AI litigation.
- Q2 fiscal 2027 revenue increased 4% year-over-year to $174.5 million, with subscription revenue accounting for $162.6 million (93% of total revenue).
- Net income dropped 44% year-over-year to $34.7 million, with operating margin declining as cost of revenue rose 54% due to AI and cloud infrastructure costs.
- Repurchased 2.51 million shares of Class A common stock in Q2 for $54.4 million, leaving $346.7 million authorized under the share repurchase program.
- ·PR Newswire: Technology NewsLegal/Regulatory
Doximity Faces Securities Fraud Class Action Lawsuit
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Doximity, Inc. (NYSE: DOCS) for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint claims Doximity made false and misleading statements, overstating the positive impact of its Newsfeed product on revenue growth and misleading investors about its advertising delivery methods, which included banner ads and newsletters. The class period is from August 8, 2024, to May 13, 2026, with a deadline of November 16, 2026, for investors to seek lead plaintiff appointment. Investors who purchased shares during this period may be eligible for recovery.
- SBS files class action lawsuit against Doximity for securities fraud violations.
- Class period: August 8, 2024 to May 13, 2026.
- Deadline for lead plaintiff appointment: November 16, 2026.
- ·DoximityProduct & Platform Launch
Novant Health Partners with Doximity to Bring Evidence-Based Clinical AI Into Epic
Doximity announces new partnerships with Novant Health and Penn Highlands Healthcare to deploy its Clinical AI Suite, and releases the 2026 Physician Compensation Report highlighting AI fluency as a career advantage.
Sermo
Recent Signals
No recent market signals documented for Sermo in the current tracking window.
Start with a company or market. Track what changes.
Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.
Doximity vs. Sermo
Compare capabilities, ecosystem relationships, and recent signals side by side in Polaris7.
Company Comparisons
Compare capabilities, ecosystem relationships, and recent signals side by side in Polaris7.
